BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 26743600)

  • 1. The Antifibrotic Effect of α2AP Neutralization in Systemic Sclerosis Dermal Fibroblasts and Mouse Models of Systemic Sclerosis.
    Kanno Y; Shu E; Kanoh H; Seishima M
    J Invest Dermatol; 2016 Apr; 136(4):762-769. PubMed ID: 26743600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alpha2-antiplasmin regulates the development of dermal fibrosis in mice by prostaglandin F(2α) synthesis through adipose triglyceride lipase/calcium-independent phospholipase A(2).
    Kanno Y; Kawashita E; Kokado A; Okada K; Ueshima S; Matsuo O; Matsuno H
    Arthritis Rheum; 2013 Feb; 65(2):492-502. PubMed ID: 23124680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. α2AP regulates vascular alteration by inhibiting VEGF signaling in systemic sclerosis: the roles of α2AP in vascular dysfunction in systemic sclerosis.
    Kanno Y; Shu E; Kanoh H; Matsuda A; Seishima M
    Arthritis Res Ther; 2017 Feb; 19(1):22. PubMed ID: 28159016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decrease in matrix metalloproteinase‑3 activity in systemic sclerosis fibroblasts causes α2‑antiplasmin and extracellular matrix deposition, and contributes to fibrosis development.
    Niwa H; Kanno Y; Shu E; Seishima M
    Mol Med Rep; 2020 Oct; 22(4):3001-3007. PubMed ID: 32945390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-30c attenuates fibrosis progression and vascular dysfunction in systemic sclerosis model mice.
    Kanno Y; Shu E; Niwa H; Seishima M; Ozaki KI
    Mol Biol Rep; 2021 Apr; 48(4):3431-3437. PubMed ID: 33913094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The nuclear receptor constitutive androstane receptor/NR1I3 enhances the profibrotic effects of transforming growth factor β and contributes to the development of experimental dermal fibrosis.
    Avouac J; Palumbo-Zerr K; Ruzehaji N; Tomcik M; Zerr P; Dees C; Distler A; Beyer C; Schneider H; Distler O; Schett G; Allanore Y; Distler JH
    Arthritis Rheumatol; 2014 Nov; 66(11):3140-50. PubMed ID: 25155144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages.
    Maier C; Ramming A; Bergmann C; Weinkam R; Kittan N; Schett G; Distler JHW; Beyer C
    Ann Rheum Dis; 2017 Jun; 76(6):1133-1141. PubMed ID: 28209630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. alpha2-antiplasmin is associated with the progression of fibrosis.
    Kanno Y; Kawashita E; Minamida M; Kaneiwa A; Okada K; Ueshima S; Matsuo O; Matsuno H
    Am J Pathol; 2010 Jan; 176(1):238-45. PubMed ID: 20008146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Autotaxin/Lysophosphatidic Acid/Interleukin-6 Amplification Loop Drives Scleroderma Fibrosis.
    Castelino FV; Bain G; Pace VA; Black KE; George L; Probst CK; Goulet L; Lafyatis R; Tager AM
    Arthritis Rheumatol; 2016 Dec; 68(12):2964-2974. PubMed ID: 27390295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic Sclerosis.
    Soare A; Györfi HA; Matei AE; Dees C; Rauber S; Wohlfahrt T; Chen CW; Ludolph I; Horch RE; Bäuerle T; von Hörsten S; Mihai C; Distler O; Ramming A; Schett G; Distler JHW
    Arthritis Rheumatol; 2020 Jan; 72(1):137-149. PubMed ID: 31350829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The transcription factor Fra-2 regulates the production of extracellular matrix in systemic sclerosis.
    Reich N; Maurer B; Akhmetshina A; Venalis P; Dees C; Zerr P; Palumbo K; Zwerina J; Nevskaya T; Gay S; Distler O; Schett G; Distler JH
    Arthritis Rheum; 2010 Jan; 62(1):280-90. PubMed ID: 20039427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of activator protein 1 signaling abrogates transforming growth factor β-mediated activation of fibroblasts and prevents experimental fibrosis.
    Avouac J; Palumbo K; Tomcik M; Zerr P; Dees C; Horn A; Maurer B; Akhmetshina A; Beyer C; Sadowski A; Schneider H; Shiozawa S; Distler O; Schett G; Allanore Y; Distler JH
    Arthritis Rheum; 2012 May; 64(5):1642-52. PubMed ID: 22139817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of cadherin 11 as a mediator of dermal fibrosis and possible role in systemic sclerosis.
    Wu M; Pedroza M; Lafyatis R; George AT; Mayes MD; Assassi S; Tan FK; Brenner MB; Agarwal SK
    Arthritis Rheumatol; 2014 Apr; 66(4):1010-21. PubMed ID: 24757152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Knockout of endothelin type B receptor signaling attenuates bleomycin-induced skin sclerosis in mice.
    Akashi K; Saegusa J; Sendo S; Nishimura K; Okano T; Yagi K; Yanagisawa M; Emoto N; Morinobu A
    Arthritis Res Ther; 2016 May; 18(1):113. PubMed ID: 27209208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The inflammasome activating caspase 1 mediates fibrosis and myofibroblast differentiation in systemic sclerosis.
    Artlett CM; Sassi-Gaha S; Rieger JL; Boesteanu AC; Feghali-Bostwick CA; Katsikis PD
    Arthritis Rheum; 2011 Nov; 63(11):3563-74. PubMed ID: 21792841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon regulatory factor 7 (IRF7) represents a link between inflammation and fibrosis in the pathogenesis of systemic sclerosis.
    Wu M; Skaug B; Bi X; Mills T; Salazar G; Zhou X; Reveille J; Agarwal SK; Blackburn MR; Mayes MD; Assassi S
    Ann Rheum Dis; 2019 Nov; 78(11):1583-1591. PubMed ID: 31439591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis.
    Yoshizaki A; Yanaba K; Yoshizaki A; Iwata Y; Komura K; Ogawa F; Takenaka M; Shimizu K; Asano Y; Hasegawa M; Fujimoto M; Sato S
    Arthritis Rheum; 2010 Aug; 62(8):2476-87. PubMed ID: 20506342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis.
    Manetti M; Romano E; Rosa I; Guiducci S; Bellando-Randone S; De Paulis A; Ibba-Manneschi L; Matucci-Cerinic M
    Ann Rheum Dis; 2017 May; 76(5):924-934. PubMed ID: 28062404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis.
    Huang J; Beyer C; Palumbo-Zerr K; Zhang Y; Ramming A; Distler A; Gelse K; Distler O; Schett G; Wollin L; Distler JH
    Ann Rheum Dis; 2016 May; 75(5):883-90. PubMed ID: 25858641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2-Methoxyestradiol inhibits bleomycin-induced systemic sclerosis through suppression of fibroblast activation.
    Zhu L; Song Y; Li M
    J Dermatol Sci; 2015 Jan; 77(1):63-70. PubMed ID: 25465161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.